TCT 2022: SYMPLICITY HTN-3 Trial Data Show Sustained Long-Term Blood Pressure Reductions With Medtronic Renal Denervation Procedure

Subjects who underwent radiofrequency renal denervation (RF RDN) with the first generation Symplicity ™ renal denervation system, had a statistically significant reduction in office and ambulatory blood pressure compared to subjects in the sham control group. The data were presented today as Late-Breaking Clinical Science at the 34th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation, and published simultaneously in The Lancet.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news